Control of MRSA in healthcare settings requires rapid and accurate tests to detect colonized patients.
- Approximately 171,200 healthcare-associated MRSA infections are acquired annually in the European Union (EU), resulting in 5,400 attributable deaths, more than 1 million excess days of hospitalization and €380 million in excess in-hospital costs1
- Between 2 and 53 million people are estimated to carry MRSA worldwide2
- The average length of stay (LOS) for all MRSA patients in the EU is 11.5 days with an average attributable cost of €7,478 per patient3
(1)KöckR, et al. Systematic Literature Analysis and Review of Targeted Preventive Measures to Limit Healthcare-Associated Infections by Meticillin-Resistant Staphylococcus Aureus. Euro Surveill. 2014 Jul 24;19(29):20860.
(2)Grundmann H, et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006 Sep 2;368(9538):874-85.
(3)Macedo-Viñas M, et al. Burden of Meticillin-Resistant Staphylococcus Aureus Infections at a Swiss University Hospital: Excess Length of Stay and Costs. J Hosp Infect. 2013 Jun;84(2):132-7.